ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Pediatric rheumatology"

  • Abstract Number: 2677 • ACR Convergence 2025

    Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease

    Timothy Brandon1, Rui Xiao2, Daniel Lovell3, Edward Oberle4, Matthew Stoll5, Nancy A. Chauvin6, Michael Francavilla7, Walter P. Maksymowych8 and Pamela Weiss9, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Nationwide Children's Hospital, Columbus, OH, 5University of Alabama at Birmingham, Birmingham, AL, 6The Cleveland Clinic, Hummelstown, PA, 7Department of Pediatric Radiology, Children’s Hospital Philadelphia, Philadelphia, PA, 8Department of Medicine, University of Alberta, 568 Heritage Building, Edmonton, AB, Canada, 9Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: This study assessed the timeline for the resolution of inflammation, changes in structural lesions at the sacroiliac joints (SIJ), and their correlation with patient-reported…
  • Abstract Number: 2156 • ACR Convergence 2025

    Bridging the Gap: Juvenile Spondyloarthritis (JSpA) vs. Chronic Non-Bacterial Osteomyelitis (CNO)

    Sophia Elfrink1, Timothy Brandon1, Jahan Jazayeri1 and Pamela Weiss2, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Childrens Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: The relationship between juvenile spondyloarthritis (JSpA) and chronic nonbacterial osteomyelitis (CNO) remains poorly defined. This study aimed to assess the proportion of pediatric patients…
  • Abstract Number: 2132 • ACR Convergence 2025

    The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-To-Adult Rheumatology Transition Program, Reduces Median Time between Final Pediatric, First Adult, and Second Adult Visits

    Ayah Eltoum1, Eileen Rife2, Livie Timmerman3, Emily Smitherman4, Melissa Mannion4 and John Bridges5, 1University of Alabama at Birmingham, Hoover, AL, 2University of Alabama Birmingham, Vestavia Hills, AL, 3University of Alabama at Birmingham, Gardendale, AL, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL

    Background/Purpose: The transition from pediatric to adult-oriented rheumatology care is a critical period for young adults with childhood-onset rheumatic diseases. The Bridge to Adult Care…
  • Abstract Number: 1818 • ACR Convergence 2025

    Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity

    Desire Casares Marfil1, Gülşah Kavrul Kayaalp2, Vafa Guliyeva2, Özlem Akgün2, Şeyma Türkmen3, Elif Kilic Konte4, Seher Şener5, Sezgin Sahin4, Ozgur Kasapcopur6, Betul Sozeri7, Selçuk Sözer Tokdemir8, Seza Özen9, Nuray Aktay Ayaz2 and Amr Sawalha1, 1University of Pittsburgh, Pittsburgh, PA, 2Istanbul University Faculty of Medicine, Istanbul, Turkey, 3University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, 4Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 5Hacettepe University Faculty of Medicine, Ankara, Turkey, 6Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, 7Health sciences university, Istanbul, Turkey, 8Istanbul University, Istanbul, Turkey, 9Hacettepe University Medical Faculty, Ankara, Turkey

    Background/Purpose: Childhood-onset lupus is generally associated with a more severe disease course than adult-onset lupus. DNA methylation alterations are known to play a key role…
  • Abstract Number: 1691 • ACR Convergence 2025

    Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm

    Andrea Gutierrez1, Stephanie Armendariz2, Muniza Mogri3 and Kristina Ciaglia4, 1UT Southwestern Medical Center, Dallas, TX, 2Texas Scottish Rite Hospital, Dallas, TX, 3UT Southwestern Medical Center / Children’s Health Dallas, Dallas, TX, 4UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX

    Background/Purpose: Patients with childhood-onset systemic lupus erythematosus (cSLE) are at increased risk of low bone mineral density, with studies showing a 40% frequency of osteopenia (Lilleby,…
  • Abstract Number: 1295 • ACR Convergence 2025

    Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America

    Martha Rodriguez1, Ekemini Ogbu2, Ashley Danguecan3, Marietta De Guzman4, Alexandra Theisen5, Lawrence Ng6, Andrea Knight3 and Ryann Kammeyer7, 1Riley Hospital For Children at Indiana University, Indianapolis, IN, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Hospital for Sick Children, Toronto, ON, Canada, 4Baylor College of Medicine, Houston, TX, 5University of Arkansas, Little Rock, AR, 6The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, 7University of Colorado, Denver, CO

    Background/Purpose: Neuropsychiatric involvement in Systemic Lupus Erythematosus (NPSLE) is a major cause of morbidity and mortality, particularly among children who are still developing neurologically. Despite…
  • Abstract Number: 1279 • ACR Convergence 2025

    Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.

    Reagan Reid1, Huayun Hou2, Isha Datar2, Daniela Dominguez3, Andrea Knight4, Deborah Levy5, Lawrence Ng6, Zhaoyu Ding2, Michael Wilson2, Lauren Erdman7, Eleanor Pullenayegum2 and Linda Hiraki5, 1The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2SickKids Research Institute, Toronto, ON, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, 7University of Cincinnati, Cincinnati, OH

    Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a clinically and genetically heterogeneous disease. We aimed to define subgroups of new diagnosis patients based on treatment…
  • Abstract Number: 0820 • ACR Convergence 2025

    Novel Autoantibodies Predictive of Atherosclerosis Progression and Statin Response in Juvenile-Onset Systemic Lupus Erythematosus

    Junjie Peng1, Pierre Donnes1, Thomas McDonnell1, Laura Schanberg2, Stacy Ardoin3, Laura Lewandowski4, George Robinson1, Elizabeth C Jury1 and Coziana Ciurtin1, 1University College London, London, United Kingdom, 2Duke University Medical Center, DURHAM, NC, 3Nationwide Children's Hospital, Columbus, OH, 4NIAMS, NIH, Bethesda, MD

    Background/Purpose: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (JSLE). There is an urgent need to identify…
  • Abstract Number: 0403 • ACR Convergence 2025

    IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial

    Ekaterina Alexeeva1, Tatiana Dvoryakovskaya1, Elena Zholobova2, Elizaveta Krekhova3, Valeria Matkava4, Rinat Raupov5, Daria Bukhanova6, Alina Egorova6, Sergey Grishin6, Mikhail Samsonov6, Mikhail Kostik7 and Irina Nikishina4, 1National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, 2I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, 3National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, 4V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, 5H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, 6R-Pharm JSC, Moscow, Russia, 7Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia

    Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
  • Abstract Number: 0128 • ACR Convergence 2025

    Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research

    Jheel Bhatt1, Elizabeth Sloan2, Selcan Demir3, Mojca Avramovic4, Seza Özen5, Doruk Erkan6 and Tadej Avcin7, 1Advent Health Orlando, Orlando, FL, 2UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 3Eskisehir Osmangazi University, Eskişehir, Turkey, 4University Children's Hospital, Ljubljana, Slovenia, 5Hacettepe University Medical Faculty, Ankara, Turkey, 6Hospital for Special Surgery, New York, NY, 7University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
  • Abstract Number: 2675 • ACR Convergence 2025

    RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis

    Ilaria Maccora1, Mariia Pavlenko2, Mekibib Altaye3, Hermine Brunner4, Alexandra Duell4, Megan Quinlan-Waters5, Alyssa Sproles6, Sherry Thornton4, Grant Schulert4, Virginia Miraldi Utz4 and Sheila Angeles-Han6, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, 3Cincinnati Children's Hospital, Cincinnati, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, CCHMC, 6Cincinnati Children's Hospital, Cincinnati, OH

    Background/Purpose: Pediatric chronic anterior uveitis (CAU) leads to sight-threatening complications in approximately 50% of affected children. Among complications, cataract and glaucoma are among the most…
  • Abstract Number: 2155 • ACR Convergence 2025

    A Novel TNFAIP3 Mutation Associated with Large Vessel Vasculitis: Expanding the Phenotypic Spectrum of A20 Haploinsufficiency

    Sirada Panupattanapong1, roshini Abraham2, Urekha Karri3, Harry Lesmana1 and Daniella Schwartz4, 1Cleveland Clinic Foundation, Cleveland, OH, 2Nationwide Children's Hospital, Columbus, OH, 3School of public health, Pittsburgh, PA, 4University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Loss-of-function pathogenic variants in TNFAIP3 lead to haploinsufficiency of A20 (HA20), a complex immune dysregulation disorder that can mimic Behcet’s disease, IBD, periodic fever…
  • Abstract Number: 2131 • ACR Convergence 2025

    Transition from Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype

    Austen Grooms1, Ioannis Karageorgiou2, Kerry Mychaliska2 and James Birmingham3, 1William Beaumont University Hospital, Auburn Hills, MI, 2William Beaumont University Hospital, Royal Oak, MI, 3River City Rheumatology, Grand Rapids, MI

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory disease primarily affecting muscle, skin, and vasculature. Characterized by muscle weakness, distinctive skin lesions, and autoantibodies, it…
  • Abstract Number: 1816 • ACR Convergence 2025

    Single-Cell RNA-Transcriptomics of JDM Skin Identifies JDM-Associated Immune Cell Populations and Dysregulated Interferon Signaling in Immune and Endothelial Cells

    Chioma Madubata1, Jessica Neely2, Christine Goudsmit3, Celine Berthier4, Zilan Zheng5, Sophia Matossian4, Jeffrey Dvergsten6, Andrew Heaton7, J. Michelle Kahlenberg4, Gabrielle Fragiadakis8 and Jessica Turnier9, 1UCSF, SF, CA, 2UCSF, San Francisco, CA, 3University of Michigan, Ann Arbor, 4University of Michigan, Ann Arbor, MI, 5University of California, San Francisco, San Francisco, CA, 6Duke University Hospital, Hillsborough, NC, 7Cure JM Foundation, Anthony, FL, 8UCSF, San Francisco, 9University of Michigan, Saline, MI

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. JDM often presents with rash, and skin inflammation is more refractory to…
  • Abstract Number: 1673 • ACR Convergence 2025

    Is Transient Synovitis of the Hip preclinical Juvenile SpA ? A follow-up study

    Anirudh Bandu1, Michal Cidon2 and Michael Weisman3, 1CHLA, Los Angeles, NJ, 2Children's Hospital of Los Angeles, Los Angeles, CA, 3Cedars-Sinai Medical Center, LOS ANGELES, CA

    Background/Purpose: Transient synovitis (TS) of the hip is considered a common, self-limited condition in the pediatric population. However, recurrences can occur; these may signal an…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology